Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
Globe Newswire•12/11/2026•08:00 ET
0
Key Highlights
- ➤Operating loss improved 24% year over year to $2.1 million
- ➤Third-quarter gross margin expanded to 69.5% from 65.2%
- ➤Nine-month net sales rose 13% to $6.6 million
- ➤Console sales increased 88% year-to-date to 32 units
- ➤FDA 510(k) submitted to expand Aquadex use to pediatric patients weighing five kilograms and above
Expert Statements
Mike McCormick, President and Chief Executive of Nuwellis
“We have made meaningful progress in strengthening Nuwellis both commercially and financially. Year to date, console unit sales have nearly doubled, expanding our installed base and creating a larger opportunity to grow recurring circuit revenue. Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment.”
Mike McCormick, President and Chief Executive of Nuwellis
“Further, by expanding gross margins and maintaining disciplined cost management, we significantly narrowed our operating loss and cash use during the quarter while continuing to invest in the areas that matter most to our long-term growth.”
Mike McCormick, President and Chief Executive of Nuwellis
“We also delivered on several key strategic initiatives, including the submission of a 510(k) to the FDA to expand the Aquadex label to pediatric patients weighing as little as five kilograms, which, if cleared, could expand access and increase adoption. In addition, we secured distribution agreements with Atrility Medical and Zorro-Flow, which broaden our product offering in a capital-efficient manner through our established commercial infrastructure. We believe these achievements position Nuwellis for sustainable growth and long-term value creation for patients, customers and shareholders.”
Console unit sales increased 88% year-to-date versus prior-year period, expanding its installed base to drive future recurring circuit revenue
Advanced growth strategy with 510(k) submission for Aquadex label expansion and two product portfolio-expanding agreements leveraging existing sales force
Get started
Create a free account to read the full story.